4 hours ago
For World COPD Day, Vickram Tejwani, MD, says single exacerbations warrant urgency and calls out gaps in spirometry use and initial COPD therapy.
9 hours ago
Sparsentan, B cell therapies, and TRPC6 and APOL1 inhibitors may each fit a different stage and cause of FSGS.
10 hours ago
A renal pathologist explains how biopsy findings, clinical context, anti-nephrin antibodies and genetics shape FSGS workup.
10 hours ago
In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.
12 hours ago
At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.